Abstracts tagged "pain"

Abstract Number: 1213 • ACR Convergence 2021
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
Christoph Baerwald¹, Edgar Stemmler², Sixten Gnuechtel², Katharina Birkner², Carsten Holland³, Bjoern Fritz², Daniela Adolf⁴ and Ralf Baron⁵, ¹University Hospital Leipzig, Leipzig, Germany, ²AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ³AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁴StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁵University Hospital Schleswig-Holstein, Kiel, Germany
Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
Abstract Number: 1704 • ACR Convergence 2021
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
Elena Pogozheva¹, Andrey Karateev¹, Evgeniy Nasonov¹, Alexander Lila¹, Vadim Mazurov², Rusanna Samigullina³, Diana Chakieva⁴, Anna Dadalova⁴, Anna Dyo⁴, Andrey Baranov⁵, Natalia Lapkina⁵, Ekaterina Kol’tsova⁶, Ivan Shchendrigin⁷, Tatyana Rasevich⁸, Antonina Davydova⁹, Irina Shafieva¹⁰, Inna Bashkova¹¹, Daria Bobrikova¹², Irina Kushnir¹³, Elena Kalinina¹⁴, Tatiana Sal’nikova¹⁵, Valentina Sorotskaya¹⁶, Irina Marusenko¹⁷, Olga Semagina¹⁸, Irina Vinogradova¹⁹, Diana Krechikova²⁰, Natalia Kiryukhina²¹, Irina Semizarova²², Dzhamilya Murtazalieva²³ and Marina Semchenkova²⁴, ¹V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ²Mechnikov North-Western State Medical University, Saint Petersburg, Russia, ³Mechnikov North-Western State Medical University, St.Petersburg, Russia, ⁴Mechnikov North-Western State Medical University, St. Petersburg, Russia, ⁵Yaroslavl State Medical University, Yaroslavl, Russia, ⁶Scientific and Research Institute of Health Care Organization, Moscow, Russia, ⁷Stavropol Regional Clinical Hospital, Stavropol, Russia, ⁸Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, ⁹Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, ¹⁰Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, ¹¹Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, ¹²Regional Clinical Hospital No. 1, Tyumen', Russia, ¹³Kemerovo regional clinical hospital, Kemerovo, Russia, ¹⁴Volgograd State Medical University, Volgograd, Russia, ¹⁵Regional Clinical Hospital, Tula, Russia, ¹⁶Tula State Medical University, Tula, Russia, ¹⁷Petrozavodsk State University, Petrozavodsk, Russia, ¹⁸Regional Clinical Hospital, Samara, Russia, ¹⁹Regional Clinical Hospital, Ulyanovsk, Russia, ²⁰Smolensk State Medical University, Smolensk, Russia, ²¹National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, ²²Regional Clinical Hospital, Krasnodar, Russia, ²³Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, ²⁴Medical Clinical Centre, Smolensk, Russia
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…
Abstract Number: 0211 • ACR Convergence 2021
Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database
David Demanse¹, László B. Tankó², Patrick Lustenberger³, Philipp Nikolaus³, Ilja Rasin³, Damian F. Brennan³, Franziska Saxer², Ronenn Roubenoff⁴, Sumehra Premji¹, Philip Conaghan⁵ and Matthias Schieker⁴, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³IBM Switzerland AG, Zürich, Switzerland, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Osteoarthritis (OA) is a chronic disabling disease, for which there are only limited treatment options. One major challenge in the development of effective treatment…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
Abstract Number: 1236 • ACR Convergence 2021
Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
Anthony Sebba¹, Duzhe Wang², Bochao Jia², Jason Troutt², Julie Birt², Amanda Quebe³ and Peter C Taylor⁴, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indanapolis, IN, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (BARI) is a Janus kinase (JAK)1/JAK2 inhibitor which provides improvements to clinical signs, symptoms, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis…
Abstract Number: 1760 • ACR Convergence 2021
Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
Jesse Dabit¹, Maria Valenzuela-Almada², Mehmet Hocaoglu³, Sebastian Vallejo-Ramos¹, Shirley-Ann Osei-Onomah¹, Sara Achenbach¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic condition that can be associated with both acute and chronic musculoskeletal pain as well as fibromyalgia. Opioids…
Abstract Number: 0229 • ACR Convergence 2021
The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education
Cristina Drenkard¹, Kirk Easley¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹, Teresa Brady² and S Sam Lim³, ¹Emory University, Atlanta, GA, ²Clarity Consulting and Communications, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Fatigue and pain are pervasive symptoms that cause escalating distress in patients with SLE, particularly among Black women and other high-risk groups. While these…
Abstract Number: 0733 • ACR Convergence 2021
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Emmanuel Maheu¹, Sandrine Soriot-Thomas², Eric Noël³, Hervé Ganry⁴, Eric Lespessailles⁵ and Bernard Cortet⁶, ¹Saint-Antoine Hospital, Paris, France, ²CHU Amiens Picardie, Amiens, France, ³Santy Orthopaedic Center, Lyon, France, ⁴Hergan Consulting 4U, Amiens, France, ⁵CH Orléans, ORLEANS, France, ⁶CHU Lille, Lille, France
Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…
Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1901 • ACR Convergence 2021
Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project
Yvonne Golightly¹, Carolina Alvarez¹, Marian Hannan², Lucy Gates³, Becki Cleveland⁴, Amanda Nelson¹ and Leigh Callahan⁵, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ³University of Southampton, Southampton, United Kingdom, ⁴Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ⁵University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Foot symptoms (i.e., pain, aching, and stiffness [PAS]) are common in middle-aged to older adults and are linked to restricted physical activity, poorer physical…
Abstract Number: 0234 • ACR Convergence 2021
Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Louis Bessette¹, Beatriz Joven-Ibáñez², Carlo Selmi³, Naijun Chen⁴, Koji Kato⁵, Ralph Lippe⁶, Patrick Zueger⁷, Jayeshkumar Patel⁴ and Joseph Merola⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ²University Hospital 12 de Octubre, Madrid, Spain, ³Humanitas Research Hospital and Humanitas University, Milan, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁷AbbVie Inc., Mettawa, IL, ⁸Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
Abstract Number: 1902 • ACR Convergence 2021
Gait Alterations Associated with Worsening Knee Pain over 2 Years: A Machine-learning Approach in the MultiCenter Osteoarthritis Study
Kathryn Bacon¹, David Felson², S. Reza Jafarzadeh¹, Vijay Kolachalama¹, Jeff Hausdorff³, Eran Gazit⁴, Neil Segal⁵, Cora Lewis⁶, Michael Nevitt⁷ and Deepak Kumar², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³Tel Aviv University, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵University of Kansas Medical Center, Iowa City, IA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Altered gait is related to structural worsening of knee osteoarthritis (OA). However, it is not known if altered gait is associated with increased risk…
Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, José Correa-Fernández⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].